118 related articles for article (PubMed ID: 38129211)
1. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy.
Manzar GS; Alam MBE; Lynn EJ; Karpinets TV; Harris T; Lo D; Yoshida-Court K; Napravnik TC; Sammouri J; Lin D; Andring LM; Bronk J; Wu X; Sims TT; Mathew G; Schmeler KM; Eifel PJ; Jhingran A; Lin LL; Joyner MM; Zhang J; Futreal A; Klopp AH; Colbert LE
Brachytherapy; 2024; 23(2):123-135. PubMed ID: 38129211
[TBL] [Abstract][Full Text] [Related]
2. T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies.
Nenclares P; Larkeryd A; Manodoro F; Lee JY; Lalondrelle S; Gilbert DC; Punta M; O'Leary B; Rullan A; Sadanandam A; Chain B; Melcher A; Harrington KJ; Bhide SA
Front Oncol; 2023; 13():1296948. PubMed ID: 38234396
[TBL] [Abstract][Full Text] [Related]
3. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
4. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM
Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895
[TBL] [Abstract][Full Text] [Related]
5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
7. HPV transcript expression affects cervical cancer response to chemoradiation.
Ruiz FJ; Inkman M; Rashmi R; Muhammad N; Gabriel N; Miller CA; McLellan MD; Goldstein M; Markovina S; Grigsby PW; Zhang J; Schwarz JK
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34255749
[TBL] [Abstract][Full Text] [Related]
8. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects.
Peng S; Tomson TT; Trimble C; He L; Hung CF; Wu TC
Gene Ther; 2006 Feb; 13(3):257-65. PubMed ID: 16177818
[TBL] [Abstract][Full Text] [Related]
9. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.
Peng S; Qiu J; Yang A; Yang B; Jeang J; Wang JW; Chang YN; Brayton C; Roden RBS; Hung CF; Wu TC
Cell Biosci; 2016; 6():16. PubMed ID: 26918115
[TBL] [Abstract][Full Text] [Related]
10. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
[TBL] [Abstract][Full Text] [Related]
12. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
[TBL] [Abstract][Full Text] [Related]
13. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Pecorelli S; Parham GP
Cancer; 1998 Dec; 83(11):2346-52. PubMed ID: 9840534
[TBL] [Abstract][Full Text] [Related]
14. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16
Colbert LE; El MB; Lynn EJ; Bronk J; Karpinets TV; Wu X; Chapman BV; Sims TT; Lin D; Kouzy R; Sammouri J; Biegert G; Delgado Medrano AY; Olvera A; Sastry KJ; Eifel PJ; Jhingran A; Lin L; Ramondetta LM; Futreal AP; Jazaeri AA; Schmeler KM; Yue J; Mitra A; Yoshida-Court K; Wargo JA; Solley TN; Hegde V; Nookala SS; Yanamandra AV; Dorta-Estremera S; Mathew G; Kavukuntla R; Papso C; Ahmed-Kaddar M; Kim M; Zhang J; Reuben A; Holliday EB; Minsky BD; Koong AC; Koay EJ; Das P; Taniguchi CM; Klopp A
Cancer Immunol Res; 2022 Feb; 10(2):259-271. PubMed ID: 35045973
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics analysis of HPV-68 E6 and E7 oncoproteins for designing a therapeutic epitope vaccine against HPV infection.
Dong D; Zhu Y; Aili Z; Chen Z; Ding J
Infect Genet Evol; 2020 Jul; 81():104266. PubMed ID: 32114254
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation.
DeWeese TL; Walsh JC; Dillehay LE; Kessis TD; Hedrick L; Cho KR; Nelson WG
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):145-54. PubMed ID: 9054890
[TBL] [Abstract][Full Text] [Related]
17. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
19. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
[TBL] [Abstract][Full Text] [Related]
20. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
